Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,680   -0,060   (-0,23%) Dagrange 25,380 - 25,780 76.465   Gem. (3M) 99,2K

Galapagos november 2019

5.599 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 280 »» | Laatste | Omlaag ↓
  1. holenbeer 1 november 2019 15:58
    quote:

    Beur schreef op 1 november 2019 15:34:

    By Carolyn Y. Johnson
    Oct. 31, 2019 at 5:15 p.m. GMT+1

    Long-awaited cystic fibrosis drug could turn deadly disease into a manageable condition

    A new cystic fibrosis therapy dramatically improved patients’ lung function and showed clear signs of targeting the genetic root of the disease, instead of just alleviating symptoms — a breakthrough so long-sought that many doctors and patients are moved to tears when talking about it.

    The data, being unveiled Thursday at a national conference in Tennessee and simultaneously published in two leading medical journals, was so persuasive that the Food and Drug Administration last week approved the three-drug combination, called Trikafta — five months ahead of the agency’s deadline. The drug could benefit 90 percent of patients with the disease, a major advance over previous drugs that worked in a tiny fraction of the people with the disease or had more modest effects.

    “I’m overjoyed,” said Francis Collins, the director of the National Institutes of Health, who was part of one of the teams that in 1989 discovered the gene defect that causes cystic fibrosis. “Thirty years along, with many bumps along the road and so many people waiting and hoping that something like this would happen — and here we are.”

    The drug is the product of decades of steady, incremental scientific work that began with research in academic laboratories and was pushed forward and funded by patient advocates through an unusual “venture philanthropy” model now being emulated by other patient groups. The leap forward was preceded by many steps — Trikafta is the fourth therapy developed by Vertex Pharmaceuticals, a Boston-based company that has built a lucrative franchise around the disease.

    www.washingtonpost.com/health/2019/10...
    Nou, dan heeft GLPG mooi op tijd de CF-boedel overgadaan aan Abbvie. Misschien ooit nog onderdeel van een Quadkafta, en dan nog royalties ook.

    Wel super dat dit nu gerealiseerd is, en eigenlijk hoop en verwacht ik zoieits ooit ook m.b.t. IPF van GLPG. Kan nog 10 jaar duren, maar de combo's gaan komen.
  2. holenbeer 1 november 2019 16:21
    quote:

    Just lucky schreef op 1 november 2019 16:13:

    [...]Misschien heeft hij wel 3 mln cash staan, weten wij veel....
    Ja, maar dan ga je niet voor 0,15 calls schrijven, lijkt me.

    Een kortere callspread is lucratiever en minder riskant, bv. nov 170-180. Levert een paar euro op en die kan je dan altijd nog doorrollen naar december.
  3. forum rang 7 Just lucky 1 november 2019 16:24
    quote:

    holenbeer schreef op 1 november 2019 16:21:

    [...]
    Ja, maar dan ga je niet voor 0,15 calls schrijven, lijkt me.

    Een kortere callspread is lucratiever en minder riskant, bv. nov 170-180. Levert een paar euro op en die kan je dan altijd nog doorrollen naar december.
    Ja uiteraard, heb je gelijk in.
5.599 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 280 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.